Macrophage infiltration is a hallmark of dystrophin-deficient muscle. We tested the hypothesis that Duchenne muscular dystrophy (DMD) patients would have elevated levels of the macrophage-synthesized pterins, neopterin and 7,8-dihydroneopterin, compared with unaffected age-matched control subjects. Urinary neopterin/creatinine and 7,8-dihydroneopterin/creatinine were elevated in DMD patients, and 7,8-dihydroneopterin/creatinine was associated with patient age and ambulation. Urinary 7,8-dihydroneopterin corrected for specific gravity was also elevated in DMD patients. Given that 7,8-dihydroneopterin is an antioxidant, we then identified a potential role for 7,8-dihydroneopterin in disease pathology. We assessed whether 7,8-dihydroneopterin could: (i) protect against isometric force loss in wild-type skeletal muscle exposed to various pro-oxidants; and (ii) protect wild-type and mdx muscle from eccentric contraction-induced force loss, which has an oxidative component. Force loss was elicited in isolated extensor digitorum longus (EDL) muscles by 10 eccentric contractions, and recovery of force after the contractions was measured in the presence of exogenous 7,8-dihydroneopterin. 
INTRODUCTION
7,8-Dihydroneopterin is a potent, non-selective antioxidant synthesized by macrophages that are activated by -interferon during immune stimulation (Wachter, Fuchs, Hausen, Reibnegger, & Werner, 1989 ). 7,8-Dihydroneopterin and its oxidized form, neopterin, are used as clinical markers of monocyte/macrophage activation (Fuchs, Weiss, & Wachter, 1993) , exercised-induced immune activation and oxidative c 2018 The Authors. Experimental Physiology c 2018 The Physiological Society stress (Lindsay et al., 2015a, b) . Since the discovery of the antioxidant
New Findings
• What is the central question of this study?
We examined whether the macrophage-synthesized antioxidant 7,8-dihydroneopterin was elevated in Duchenne muscular dystrophy (DMD) patients. We then examined whether 7,8-dihydroneopterin could protect dystrophic skeletal mouse muscle from eccentric contraction-induced force loss and improve recovery.
• What is the main finding and its importance?
Urinary neopterin/creatinine and 7,8-dihydroneopterin/ creatinine were elevated in DMD patients. 7,8-Dihydroneopterin attenuated eccentric contraction-induced force loss of dystrophic skeletal mouse muscle and accelerated recovery of force. These results suggest that eccentric contraction-induced force loss is mediated, in part, by an oxidative component and provides a potential protective role for 7,8-dihydroneopterin in DMD.
peroxide (H 2 O 2 ; Gieseg et al., 2008) , ferrous ions (Gieseg, Maghzal, & Glubb, 2000) , copper ions (Herpfer et al., 2002) , lipid peroxyl radicals (Gieseg et al., 1995) and peroxynitrite (Herpfer et al., 2002) .
In vitro experiments with 7,8-dihydroneopterin have shown protection against protein and thiol oxidation in THP-1 cells (Gieseg & Cato, 2003) and prevented foam cell formation through reduced low-density lipoprotein oxidation (Baird, Reid, Hampton, & Gieseg, 2005) .
Duchenne muscular dystrophy (DMD) is a fatal form of muscular dystrophy characterized by a severe skeletal and cardiac muscle pathophysiology affecting approximately one in 4000 males born (Mendell et al., 2012 ). An X-chromosome mutation of the gene encoding dystrophin, a protein that is associated with the muscle sarcolemma, is responsible for the disease (Hoffman, Brown, & Kunkel, 1987) . The absence of dystrophin results in loss of the dystrophin-glycoprotein complex (Ervasti, Ohlendieck, Kahl, Gaver, & Campbell, 1990) , resulting in a deficit in a link between the extracellular matrix and muscle costameric cytoskeleton (Ervasti, 2003; Ervasti & Campbell, 1993) . Consequences of dystrophin loss include heightened susceptibility to muscle injury, incomplete muscle regeneration (Watkins & Cullen, 1985) and a chronic inflammatory state (Porter et al., 2002 ) associated with immune cell infiltration (Villalta, Nguyen, Deng, Gotoh, & Tidball, 2009 ) and oxidative stress (Tidball & Wehling-Henricks, 2007) .
Recent advancements have identified aberrant signalling pathways related to oxidavite stress that contribute to the pathophysiology of DMD (Evans, Misyak, Robertson, Bassaganya-Riera, & Grange, 2009; Tidball & Wehling-Henricks, 2007) . In the mouse model of DMD (mdx), elevated expression levels of NADPH oxidase (Shkryl et al., 2009) and its gp91 phox and p67 phox subunits (Whitehead, Yeung, Froehner, & Allen, 2010) , rapid stretch-induced increase of H 2 O 2 in skeletal muscle (Pal et al., 2014) , and protective effects of antioxidants (Buetler, Renard, Offord, Schneider, & Ruegg, 2002) provide strong evidence that oxidative stress also plays a role in dystrophic mouse muscle. In particular, mdx skeletal muscle has an exaggerated susceptibility to eccentric contraction-induced force loss (Moens, Baatsen, & Maréchal, 1993; Petrof et al., 1993) . Several mechanisms have been elucidated, and generation of reactive oxygen species (ROS) during contraction has been identified as a contributing factor (Buetler et al., 2002; Khairallah et al., 2012; Shkryl et al., 2009; Ward, Prosser, & Lederer, 2014; Whitehead, Pham, Gervasio, & Allen, 2008) .
Given that oxidative stress impacts DMD biology, that immune cell inflammation is a consequence of dystrophinopathy and that immune cells are known to release the antioxidant 7,8-dihydroneopterin, we measured urinary concentrations of 7,8-dihydroneopterin and neopterin in DMD patients and healthy age-matched control subjects with the purpose of identifying a potential role for this antioxidant in DMD pathology. We then went on to interrogate whether 7,8-dihydroneopterin could protect mdx skeletal muscle from eccentric contraction-induced force loss.
METHODS

Ethical approval
We made measurements in urine samples that had been collected from male DMD patients and healthy age-matched control subjects.
The experimental protocol was approved by the International Review Board, University of Minnesota (1207M18081), and all participants were informed of the risks involved in the study before their written consent was obtained. The studies conformed to the standards set by the latest revision of the Declaration of Helsinki, except for registration in a database.
Male mdx (C57Bl/10ScSn-DMD mdx ) and wild-type (WT) mice (C57Bl/10ScSn) aged 12 weeks were purchased from Jackson Laboratory (Bar Harbor, ME, USA). All mice were housed in groups of three or four per cage on a 14 h-10 h light-dark cycle, with food and water provided ad libitum. Experiments were completed 1 week after arrival. All animal protocols (1707-34941A) were approved by the University of Minnesota Institutional Animal Care and Use Committee. All experiments comply with the policies and regulations set out in the editorial policy of Experimental Physiology. 7, neopterin, xanthopterin and 7, xanthopterin were purchased from Schirck's Laboratory (Jona, Switzerland). Hydrogen peroxide, sodium HOCl and 3-morpholinosydnonimine-N-ethylcarbamide (SIN-1 chloride) were purchased from Sigma Chemical Company (St Louis, MO, USA).
Reagents
Study I: Determine if patients with DMD have elevated 7,8-dihydroneopterin concentrations
Participants were DMD patients (n = 47; 11.4 ± 0.6 years of age) and healthy control subjects (n = 34; 13.9 ± 1.2 years of age). At the time of urine collection, participants completed a questionnaire that included information about age and ambulation. Samples were collected mid-stream and placed on ice immediately before being transported to the laboratory, aliquoted and frozen at −80 • C until analysis. (Brooks & Faulkner, 1988) . The Krebs buffer was also immediately collected and frozen after the eccentric protocol to measure changes in 7,8-dihydroneopterin and its oxidized forms from pre-to posteccentric contractions.
Study
Isometric force recovery
To ascertain the extent to which 7,8-dihydroneopterin can enhance recovery of force in mdx muscles, we measured the recovery of isometric tetanic force after eccentric contractions in another set of EDL muscles from mdx mice. The eccentric protocol was the same as that conducted in the first experiment in study II, except that the protocol ceased when 75% of eccentric force was lost.
This was done so that if 7,8-dihydroneopterin in the bath attenuated force loss, muscles completed more contractions to attain the same force decrement before commencing the recovery protocol.
Once 75% of eccentric force loss was reached, L o was readjusted, and P o was measured at 0, 30, 60, 90 and 120 min post-eccentric contractions.
High-performance liquid chromatographic analysis of pterins
The mdx muscles were thawed on ice and homogenized using an 
Measurement of urine specific gravity
Specific gravity (SG) was calculated using a hand-held refractometer.
Fifty microlitres of each urine sample was added to the refractometer and measured using distilled water as a zero standard. Correction of neopterin and 7,8-dihydroneopterin concentrations using SG was calculated using the following formula based on the normal population SG 1.020 :
Statistical analysis
For study I, 7,8- For study III, specific P o and the change in eccentric force and recovery of isometric force by WT and mdx muscle were analysed using a two-way ANOVA. A repeated measure was applied to the eccentric contraction number, with the other factor being mouse strain with or without 7,8-dihydroneopterin. Change in isometric force, 7,8-dihydroneopterin oxidation and muscle 7,8-dihydroneopterin absorption after eccentric contractions were analysed by one-way
ANOVAs. Data are presented as means ± SD, with significance set at P < 0.05.
RESULTS
Study I
We measured Although urinary metabolites were normalized by creatinine in a previous study of DMD (Rodriguez & Tarnopolsky, 2003) , there is evidence to suggest that urinary creatinine decreases with age in patients with muscular dystrophy (Inoue, Miyake, Kanazawa, Sato, & Kakimoto, 1979) , thus potentially influencing the corrected concentrations of metabolites. We addressed this by measuring and reporting both urinary creatinine and specific gravity and show that creatinine (5.9 ± 6.6 versus 11.1 ± 7.9 mmol l −1 ; Figure 2a ; P = 0.011)
but not specific gravity (1.020 ± 0.005 versus 1.017 ± 0.009 g cm −3 ; 
Study II
Oxidant-induced isometric force loss in WT muscle
In order to test the effectiveness of 7,8-dihydroneopterin on muscle,
we first determined the effect of three pro-oxidants on WT skeletal Compared with H 2 O 2 , HOCl oxidized a greater concentration of 7,8-dihydroneopterin to dihydroxanthopterin (P < 0.01) and neopterin (P < 0.01), although the level of isometric force protection was not different (Figure 5a and b) . In the presence of SIN-1, there was no detectable 7,8-dihydroneopterin in the bath after the incubation, which was accompanied by minimal neopterin and xanthopterin and no detectable dihydroxanthopterin. To confirm the lack of detectable oxidized pterins in the presense of SIN-1, we performed an acetone/methanol precipitation experiment, which did not resolve the chromatograph, ruling out the possibility that the pterin peak was obscured by any proteins.
7,8-Dihydroneopterin protects WT muscle from oxidant-induced isometric force loss
These data show that 7,8-dihydroneopterin protects against ROSinduced muscle force drop. Thus, in study III we sought to determine whether 7,8-dihydroneopterin was capable of attenuating eccentric contraction-induced force loss of dystrophic muscle.
Study III
7,8-Dihydroneopterin attenuates eccentric contraction-induced force loss in mdx muscle
It has been reported that oxidative stress contributes to eccentric contraction-induced force loss in mdx but not WT muscle (Buetler et al., 2002; Khairallah et al., 2012; Shkryl et al., 2009; Ward et al., 2014; Whitehead et al., 2008) . Thus, we incubated isolated EDL muscles from WT and mdx mice with 0 and 6 mM 7,8-dihydroneopterin. Figure 7a shows that specific P o was lower in mdx compared with WT EDL muscles (P < 0.001) and that there was no effect of incubation in 6 mM 7,8-dihydroneopterin (P = 0.680). When EDL muscles were subjected to an eccentric contraction protocol, those from mdx mice lost more eccentric force than those from WT on contractions 2-10 ( Figure 7b ; P < 0.001). By contraction 10, WT EDL lost 15 ± 3% eccentric force compared with 74 ± 11% for mdx EDL. The addition of 7,8-dihydroneopterin did not affect WT eccentric force loss from contraction 2 to 10 (P > 0.999), but it provided protection against force loss in the mdx muscle from contraction 2 to 8 (P < 0.001), improving the final force loss to only 63 ± 16% of the first eccentric contraction. 
Force loss was reversible and recovery accelerated with 7,8-dihydroneopterin
Here, we wanted to identify whether loss of force in mdx muscle was recoverable in the presence of 7,8-dihydroneopterin. To ensure that mdx muscle with or without 7,8-dihydroneopterin began the recovery period with the same force decrement, we continued eccentric contractions until there was a loss of 75% eccentric force for each muscle (0 mM, three contractions; 6 mM, five contractions). Accordingly, isometric force immediately after the eccentric contractions did not differ between muscles exposed to 0 versus 6 mM 7,8-dihydroneopterin (time 0; Figure 8c ; P = 0.997). During the isometric contractions after the eccentric contractions (post), peak force was attained within the first 100 ms, followed by a decline in force over the remainder of the 200 ms stimulation (Figure 8a and b) . Peak isometric tetanic force recovered to 64 ± 2% of initial force 60 min after the eccentric protocol in muscle not exposed to 7,8-dihydroneopterin, which was greater in the presence of 7,8-dihydroneopterin (81 ± 5%; Figure 8c ; P < 0.010).
Eccentric contractions facilitate 7,8-dihydroneopterin absorption and oxidation in mdx muscle
The bath concentration of 7,8-dihydroneopterin did not change at 30 min of passive incubation (from 6 to 5.93 mM) but was decreased at 60 min after eccentric contractions in mdx muscle (from 5.93 to 5.09 mM; Figure 9a ; P < 0.001). This was simultaneous with an increase in the bath concentrations of dihydroxanthopterin (Figure 9b 
DISCUSSION
Oxidative stress and inflammation contribute to the pathophysiology of DMD (Evans et al., 2009; Rodriguez & Tarnopolsky, 2003; Tidball & Wehling-Henricks, 2007) , and the response of mdx muscle to eccentric contractions is a reliable and standard outcome used to test 
Oxidation of 7,8-dihydroneopterin by H 2 O 2 , HOCl and SIN-1. Incubation of EDL muscle for 60 min with 10 mM H 2 O 2 (a-c), 10 mM HOCl (d-f) or 25 mM SIN-1 (g-i) caused oxidation of 7,8-dihydroneopterin (0.02, 0.2 or 2 mM) in the bath to its respective pterins. Hypochlorite oxidized 7,8-dihydroneopterin to a greater degree than H 2 O 2 , which included the production of more neopterin. SIN-1 completely oxidized 7,8-dihydroneopterin without the detection of dihydroxanthopterin. All experiments had n = 5 per pterin concentration, with data depicted as the mean ± SD. Note that when error bars are not apparent they are within the symbol loss in dystrophic mouse muscle (Buetler et al., 2002; Khairallah et al., 2012; Shkryl et al., 2009; Ward et al., 2014; Whitehead et al., 2008) , Lindsay et al., 2015a) and have been shown to be elevated in other inflammatory diseases (Griffin, McArthur, & Cornblath, 1991) .
Our results support the evidence that dystrophic skeletal muscle is a highly oxidative environment (Allen, Whitehead, & Froehner, 2016; Tidball & Wehling-Henricks, 2007 ) associated with immune cell infiltration (Porter et al., 2002) . Given that neopterin and 7,8-dihydroneopterin are directly associated with M1 macrophage activation, the elevation in DMD patients solidifies greater levels of inflammation compared with healthy control subjects. Moreover, because 7,8-dihydroneopterin is a potent antioxidant (Gieseg et al., 2008) and we show that it is protective against force drop in mdx mouse muscle, the elevation may suggest a protective mechanism within dystrophic muscle that has not yet been described. We provided urinary concentrations of neopterin and 7,8-dihydroneopterin corrected by both creatinine and SG in study I for comparative and discussion purposes. As urine provides an accessible human tissue for DMD analysis, it is crucial that metabolite concentrations are correctly controlled. Although there is no current consensus on the most appropriate correction method in studies on DMD patients, we believe that both creatinine and SG have positive and negative attributes. Inoue et al. (1979) stated that urinary creatinine cannot be used for metabolite correction in DMD patients because creatinine concentrations change with age. However, it has been accepted in the literature, as Rodriguez and Tarnopolsky (2003) , for example, report elevated 8-hydroxy-2 ′ -deoxygunaosine in DMD patients using creatinine correction. The statement by Inoue et al. (1979) is based on the change in muscle mass of DMD patients as disease progresses, which in turn results in decreasing creatinine concentrations in the urine. Interestingly, studies on ageing and HIV patients, which also describe decreases in muscle mass, use creatinine to correct for urine metabolites (Fuchs et al., 2009; Gianni, Jan, Douglas, Stuart, & Tarnopolsky, 2004) . Thus, there is precedence for the use of creatinine correction in the presence of muscle wasting. A limitation associated with our study is the single-catch urine sample collection rather than 24 h urine samples (e.g. as used by Rodriguez & Tarnopolsky, 2003) . Although a single catch provides a representative measure of hydration and reduces sample-integrity concerns, it is not well correlated with 24 h urine collection (Heavner et al., 2006) . There is also concern that a urinary metabolite has to have similar elimination kinetics to creatinine in order to be normalized by creatinine. Neopterin and 7,8-dihydroneopterin are excreted by (Estelberge et al., 1993) , which is similar to creatinine (Eisner et al., 2010) , thus correction by creatinine satisfies these limitations.
A goal of our studies is to glean information from both DMD patients and mdx mice to determine the role of pterins in muscular dystrophy, thus it would be ideal to measure urinary metabolites by the same methods in all of our studies. However, comparisons between creatinine and SG are complicated because of the extreme density of mouse urine (Parfentjev & Perlzweig, 1933) , which makes it difficult to normalize urinary metabolite concentrations in mice.
Any urine sample that lies above the maximal density allowed for SG correction (>1.030 g cm −3 ) cannot be used accurately (Alessio, Berlin, Dell'Orto, Toffoletto, & Ghezzi, 1985) . Thus, urinary Braat et al., 2015) ; and (ii) DMD patients suffer from kidney dysfunction (Braat et al., 2015) , which directly affects glomerular filtration and thus density. For example, urinary metabolites for US specimens are normally corrected using an SG of 1.020, whereas Bangladeshi specimens are corrected using 1.015 (Miller et al., 2004) . Therefore, to correct DMD patient urinary metabolites accurately, a target population mean SG for DMD patients is imperative.
Collectively, we contend that for comparison of urinary metabolites between DMD patients and unaffected control subjects, as well as amongst mdx mice, creatinine may provide the best correction method rather than SG for single-catch urine samples.
Strategies targeting oxidant-derived mechanisms in DMD remain prominent in preclinical models (Petrillo et al., 2017) .
Macrophages also play a crucial role in DMD pathogenesis (Porter et al., 2002) , and our data showing that neopterin and 7,8-dihydroneopterin are elevated in patients with DMD corroborate the involvement of macrophages in this disease. We did not measure 7,8-dihydroneopterin in mdx mice because mice overexpress 6-pyruvoyl tetrahydropterin, which prevents 7,8-dihydroneopterin synthesis and neopterin detection (Duch, Bowers, Woolf, & Nichol, 1984) . 7,8-Dihydroneoperin is thought to protect protein, DNA and lipids from oxidative modification and provide self-protection for macrophages during immune activation (Gieseg et al., 2008) . Thus, we speculate that the regenerative capacity of dystrophic muscle would be compromised in the absence of 7,8-dihydroneopterin because it might provide oxidative buffering in the inflammatory environment.
Furthermore, the exogenous administration of 7,8-dihydroneopterin showed protection comparable to other antioxidants, such as N-acetylcysteine (Whitehead et al., 2008) . Other investigations have attenuated eccentric contraction-induced force loss with genetic manipulation of NADPH subunits (Loehr et al., 2016) or by supplementation with green tea extract (Buetler et al., 2002) , whereas here we show that 7,8-dihydroneopterin can protect skeletal muscle from force loss in the presence of common pro-oxidants, which are abundant in dystrophic muscle (Disatnik et al., 1998) .
Thus, elevated 7,8-dihydroneopterin in DMD patients may describe macrophage activation, but it may also provide a muscle-specific protective mechanism against eccentric-induced muscle force loss and, consequently, loss of muscle function.
Results of this study indicate that 7,8-dihydroneopterin scavenges ROS, preventing loss of isometric force in WT muscle. Interestingly, this same protection was not observed when muscles were exposed to a reactive nitrogen species, via SIN-1 (Figure 5c ). Although previous research has shown that 7,8-dihydroneopterin is capable of scavenging superoxide (Shen, 1994) and peroxynitrite (Herpfer et al., 2002) Differentiating between eccentric contraction-induced oxidant scavenging and increased basal level oxidant scavenging in mdx muscle compared with WT could not be discerned. We were also unable to ascertain whether the increased muscle 7,8-dihydroneopterin was within fibres or the extracellular matrix.
The restoration of isometric tetanic force within 2 h after eccentric contractions (Figure 7) suggests reversibility of the eccentric contraction-induced force loss phenotype of mdx muscle, consistent with the restoration of strength of mdx muscle in vitro and in vivo shown previously (Call, Warren, Verma, & Lowe, 2013; Han, Rader, Levy, Bansal, & Campbell, 2011) . We speculate that the improved recovery of force might result from the ROS scavenging potential of 7,8-dihydroneopterin preventing further protein modification. This might indicate the following two possibilities: (i) 7,8-dihydroneopterin prevented irreversible oxidation of key muscle proteins; and (ii) 7,8-dihydroneopterin reduced the degree of stretch-induced plasmalemma permeability and membrane inexcitability (Call et al., 2013; Pratt et al., 2013) . Interestingly, while peak isometric tetanic force recovered to 80% of initial during this recovery period, maintenance of peak force during the 200 ms contraction with or without 7,8-dihydroneopterin was not maintained (Figure 8a and b). These observations suggest that the contractile machinery, commencing with action potential propagation through to crossbridge formation, might not be completely restored after eccentric contractions in dystrophin-deficient muscle. Regardless, it is apparent that ROS play a significant role in eccentric contraction-induced force loss and recovery, providing impetus for continued antioxidant interventional studies for DMD.
Conclusion
We have demonstrated that 7,8-dihydroneopterin is elevated in patients with DMD and is associated with age and ambulation when corrected with creatinine, partly protects isolated mdx EDL muscle from eccentric contraction-induced force loss, and improves the recovery of isometric force after eccentric contractions. Protection of force generation was achieved through the absorption and oxidation of 7,8-dihydoneopterin in mdx muscle challenged by eccentric contractions. These results indicate that oxidative stress contributes to the contraction-induced force loss phenotype in dystrophin-deficient muscle and that 7,8-dihydroneopterin is capable of partly protecting skeletal muscle force in the presence of ROS.
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